Schroder J, et al. - Researchers compared the long term outcomes of stent restenosis treatment with two paclitaxel-coated balloons (PCBs): butyryl-tri-hexyl citrate (BTHC)-PCB vs iopromide-based PCB in this single centre, nonrandomized, retrospective study under real-world condition. Participants included 194 patients with 194 in-stent restenosis (ISR) treated by repeat percutaneous coronary intervention with PCBs. These subjects were examined with respect to major adverse cardiac events (MACEs), defined as cardiac death, myocardial infarction and need for target lesion revascularization (TLR) at 1 year (primary end point), as well as for MACE and TLR at long-term follow-up (secondary end points). At 1-year and long-term follow-up, comparable rates of MACE and TLR were seen with BTHC-PCB vs iopromide-based PCB.